Brazil Health Agency Recalls Paracetamol Batch Due to Mold Contamination
Brazil's National Health Surveillance Agency (Anvisa) has ordered the suspension of distribution, sale, and use of a specific batch of Paramol 750 mg (paracetamol). This action follows the discovery of tablets exhibiting signs of mold contamination. The affected batch, identified as 114053, contains 200 tablets and was manufactured by Belfar Ltda. The decision was published in the Official Gazette of the Union on Thursday, November 30th. Anvisa reported that the tablets showed signs of dirtiness, with an appearance suggestive of contamination by mold, a type of fungus commonly known as mildew. Paramol is prescribed for treating fever and alleviating mild to moderate pain. Consumers possessing any units from batch 114053 are strongly advised by Anvisa to cease using the medication immediately. They should seek guidance from a doctor or pharmacist for an appropriate replacement. For reimbursement inquiries, consumers are directed to contact the manufacturer's Customer Service (SAC). The news outlet g1 has reached out to the manufacturer for a statement and will update the report upon receiving a response.
This recall highlights the critical role of regulatory bodies like Anvisa in safeguarding public health by monitoring pharmaceutical quality. The incident underscores the inherent risks in pharmaceutical manufacturing supply chains, where contamination can occur despite quality control measures. Consumers are empowered to protect themselves by adhering to recall notices and seeking professional medical advice for medication alternatives. From a systemic perspective, such events prompt reviews of manufacturing protocols and inspection frequencies to mitigate future occurrences and maintain public trust in essential medicines. The focus remains on ensuring the integrity of pharmaceutical products to prevent adverse health outcomes.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.